Atara Biotherapeutics, Inc. (0HIY.L)

0,7066 +0,0264 (+3,88%) In data: 03:04PM BST. Mercato aperto.

Atara Biotherapeutics, Inc.

2380 Conejo Spectrum Street
Suite 200
Thousand Oaks, CA 91320
United States
805 623 4211
https://www.atarabio.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 225

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Pascal Touchon D.V.M.	President, CEO & Director	1,08M	N/D	1963
Mr. K. Amar Murugan	Executive VP & Chief Legal Officer	618,52k	N/D	1976
Mr. Eric Hyllengren	Executive VP & Chief Financial Officer	N/D	N/D	1976
Dr. Anhco Nguyen Ph.D.	Executive VP and Chief Scientific & Technical Officer	N/D	N/D	1973
Alex Chapman	Vice President of Corporate Communications & Investor Relations	N/D	N/D	N/D
Ms. Jill Henrich	Executive VP and Global Head of Regulatory Affairs & Quality	N/D	N/D	1963
Mr. Dan Maziasz	Executive VP & Chief Business Officer	N/D	N/D	N/D
Ms. Rajani Dinavahi M.D.	Senior VP & Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Governance aziendale

L'ISS Governance QualityScore di Atara Biotherapeutics, Inc. al 1 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.